Characteristic Survivors (8) Non-Survivors (5) P-value
Age (y) 8.55(0.86,18.1) 3.23(1.02,19.0) 0.8329
Race
Black 1(12.5) 0 1
White 7(87.5) 5(100)
Sex
Male 4(50) 4(80) 0.5649
Female 4(50) 1(20)
Primary diagnosis
B-cell ALL 1(12.5) 3(60) 0.223
T-cell ALL 1(12.5 0(0)
AML 4(50) 1(20)
Lymphoma 0(0) 1(20)
Neuroblastoma 2(25) 0(0)
HCT
Allogeneic 6(75) 4(80) 1
Auto 2(25) 1(20)
CKRT
CVVHD 3(37.5) 3(60) 0.5921
CVVHDF 5(62.5) 2(40)
Intubation
Yes 5(62.5) 5(100) 0.2308
No 3(37.5) 0(0)
Inotropic support
Yes 7(87.5) 4(80) 1
No 1(12.5) 1(20)
Liberation
Yes 4(50) 1(50) 1
No 4(50) 1(50)
PRISM 11(7,15) 13(10,22) 0.3333
CKRT duration (d) 4(2,21) 4(2,7) 0.9775
Time from HCT to CKRT (d) 19.5(9,49) 28(22,88) 0.1368
IMV duration (d) 41(1,249) 7(3,44) 0.5952
AKI
No/mild AKI 0(0) 3(60) 0.035
Severe AKI 8(100) 2(40)